No Data
UBS Maintains AbbVie(ABBV.US) With Hold Rating, Cuts Target Price to $181
AbbVie Is Maintained at Buy by Citigroup
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
AbbVie's Loss Is Bristol Myers Squibb's Gain - Analyst | NYSE:ABBV
Tuesday Market Finally Slows Down, Takes a Post Veterans Day Breather | Live Stock